Novel murine dendritic cell lines: a powerful auxiliary tool for dendritic cell research. by Fuertes Marraco, S.A. et al.
METHODS ARTICLE
published: 07 November 2012
doi: 10.3389/fimmu.2012.00331
Novel murine dendritic cell lines: a powerful auxiliary tool
for dendritic cell research
Silvia A. Fuertes Marraco1†‡, Frédéric Grosjean1‡, Anaïs Duval 1, Muriel Rosa1, Christine Lavanchy 1,
Devika Ashok 1, Sergio Haller 1, Luc A. Otten1, Quynh-Giao Steiner 1, Patrick Descombes2,3,
Christian A. Luber 4†, Felix Meissner 4, Matthias Mann4, Lajos Szeles5,Walter Reith5 and HansAcha-Orbea1*
1 Department of Biochemistry, Center of Immunity and Infection Lausanne, University of Lausanne, Epalinges, Switzerland
2 Genomics Platform, NCCR “Frontiers in Genetics,” University of Geneva/CMU, Geneva, Switzerland
3 Functional Genomics Core at Nestle Institute of Health Sciences, Lausanne, Switzerland
4 Department of Proteomics and Signal Transduction, Max-Planck-Institute of Biochemistry, Munich, Germany
5 Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
Edited by:
Manfred B. Lutz, University of
Wuerzburg, Germany
Reviewed by:
Elodie Segura, Institute Curie, France
William Hildebrand, University of
Oklahoma HSC, USA
*Correspondence:
Hans Acha-Orbea, Department of
Biochemistry, Chemin des
Boveresses 155, CH-1066 Epalinges,
Switzerland.
e-mail: hans.acha-orbea@unil.ch
†Present address:
Silvia A. Fuertes Marraco, Clinical
Tumor Biology and Immunotherapy
Unit, Ludwig Institute for Cancer
Research of the University of
Lausanne, Lausanne, Switzerland;
Christian A. Luber , Novo Nordisk
Inflammation Research Center,
Seattle, WA, USA.
‡Silvia A. Fuertes Marraco and
Frédéric Grosjean have contributed
equally to this work.
Research in vitro facilitates discovery, screening, and pilot experiments, often preceding
research in vivo. Several technical difficulties render Dendritic Cell (DC) research particularly
challenging, including the low frequency of DC in vivo, thorough isolation requirements,
and the vulnerability of DC ex vivo. Critically, there is not as yet a widely accepted human or
murine DC line and in vitro systems of DC research are limited. In this study, we report the
generation of new murine DC lines, named MutuDC, originating from cultures of splenic
CD8α conventional DC (cDC) tumors. By direct comparison to normal WT splenic cDC sub-
sets, we describe the phenotypic and functional features of the MutuDC lines and show
that they have retained all the major features of their natural counterpart in vivo, the splenic
CD8α cDC. These features include expression of surface markers Clec9A, DEC205, and
CD24, positive response to TLR3 and TLR9 but not TLR7 stimuli, secretion of cytokines,
and chemokines upon activation, as well as cross-presentation capacity. In addition to the
close resemblance to normal splenic CD8α cDC, a major advantage is the ease of deriva-
tion and maintenance of the MutuDC lines, using standard culture medium and conditions,
importantly without adding supplementary growth factors or maturation-inducing stimuli
to the medium. Furthermore, genetically modified MutuDC lines have been successfully
obtained either by lentiviral transduction or by culture of DC tumors originating from genet-
ically modified mice. In view of the current lack of stable and functional DC lines, these
novel murine DC lines have the potential to serve as an important auxiliary tool for DC
research.
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INTRODUCTION
Dendritic cells (DC) are the most efficient group of antigen-
presenting cells. As such, DC are highly specialized in the detection
and phagocytosis of pathogens, the processing of antigens as well
as costimulation and inflammatory signals in order to induce ade-
quate T cell responses. The potential of DC to define the quality
and extent of an adaptive immune response has attracted major
interest in vaccine science, DC being key targets to fight infectious
as well as cancer diseases (Steinman, 2008).
Dendritic cells detect microbial ligands via Pattern Recognition
Receptors (PRR) such as Toll-like Receptors (TLR; Reis e Sousa,
2004). Upon encounter with microbes, DCs are strongly acti-
vated, characterized by the upregulation of co-stimulatory mol-
ecules (CD40, CD80, CD86) and the production of cytokines and
chemokines. In order to monitor and react efficiently to a patho-
genic challenge, DC form a complex and heterogeneous network
in the organism (Shortman and Naik, 2007; Merad and Manz,
2009). Several DC subsets have been described in both humans
and mice (Shortman and Liu, 2002), the latter being the animal
model preferentially used and most accessible in the field. Migra-
tory DC capture pathogens at the site of infection and rapidly reach
the nearest draining lymph node for antigen presentation. Con-
ventional tissue-resident DC (cDC) act as sentinels in secondary
lymphoid organs and other tissues for antigen capture and pre-
sentation in situ. Other inflammatory DC may differentiate from
blood-derived monocytes and infiltrate secondary organs and tis-
sue during infection or inflammatory response. DC types may be
further subdivided into different subsets and are identified accord-
ing to the expression of surface markers. For instance in the mouse
spleen, DC subtypes include plasmacytoid DC (B220+ CD11cint
GR1−), monocyte-derived DC (MoDC; B220− CD11cint GR1±),
and cDC (B220− CD11chigh GR1−). The latter are commonly
divided into CD8α+ (CD11chigh, B220−, DEC205+, CD24high,
CD11b−) and CD8α− (CD11chigh, B220−, DEC205−, CD24low,
CD11b+, CD172+, CD4±) cDC subsets. Interestingly, several lines
of evidence support the notion of division of labor and cross-talk
within the DC network; altogether, DC subsets display differences
in the capacity to monitor tissue or circulate, the expression of
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PRRs, the production of cytokines, as well as antigen uptake and
presentation mechanisms (Reis e Sousa, 2004; Villadangos and
Schnorrer, 2007; Pulendran et al., 2008).
Further to the inherent complexity and heterogeneity of the DC
system, a number of technical challenges have set a bottleneck to
advances in DC research. First is the natural scarcity of DC in vivo,
which not only reflects their functional potency, but also is a major
limitation on the cellular material available for experimentation
(Inaba et al., 2009). Secondly, isolated splenic cDC show dramatic
activation and apoptosis in culture, clearly detectable after a few
hours of incubation (Vremec et al., 2011). This greatly hampers
experimental settings whenever relatively large quantities of cells
or long incubation times are required.
In contrast to the B-cell and T cell fields, there is not as yet a
DC line thoroughly characterized and widely accepted for in vitro
research. In the mouse model, the DC culture system that has been
widely used is Bone Marrow-derived DCs (BMDC), based on the
differentiation of DC by treatment of BM progenitors with GM-
CSF (and IL-4, depending on the protocol; Inaba et al., 2009). More
recently, BMDC are also generated using Flt3L, obtaining a mix-
ture of equivalents to both CD8α+ and CD8α− cDC subsets and
pDC (Naik et al., 2005). In human DC research, DC are similarly
derived from the culture of peripheral blood mononuclear cells or
CD14+ monocytes with GM-CSF/IL-4 (the MoDC system; Inaba
et al., 2009). In both the mouse BMDC and the human MoDC sys-
tems, DC differentiation is driven in vitro, during 6–10 days, and is
often followed by LPS treatment overnight to “mature” DC. These
methods provide large quantities of DC, but require repetitive sac-
rifice of mice or human blood sampling, and are relatively tedious
and time-consuming, as compared to the use of immortalized cell
lines.
A limited number of DC lines have been described. These
include the D1 cells, a growth factor-dependent immature DC line
derived from mouse spleen DC, which can be “matured” with LPS
(Winzler et al., 1997; Mortellaro et al., 2009). The generation of
murine DC lines based on oncogene-driven immortalization has
also been reported, including the SRDC line (Ruiz et al., 2005),
the SVDC line (Ebihara et al., 2004), and the DC 2.4 cell line
(Shen et al., 1997). In humans, DC lines can be generated from
the culture of leukemic DC found in the blood of acute myeloid
leukemia patients (Mohty et al., 2003). Other related human and
murine model cell lines used in the DC field are Raw264.7 and J774
in mice, and THP-1, HL-60 and MUTZ-3 lines in humans (San-
tegoets et al., 2008; van Helden et al., 2008). Some of the issues
generally encountered with these DC lines or model cell lines
are the requirement of particular growth factors or conditions
to maintain cultures, as well as concerns over their equivalence
to natural DC counterparts in vivo. In the light of the techni-
cal difficulties encountered in the study of DC biology, DC lines
that retain the major functions of DC (further reflecting differ-
ent subsets) and that are easily maintained in culture are still long
sought.
In recent years, we developed a transgenic mouse express-
ing the SV40LgT oncogene (with an eGFP reporter) under the
CD11c promoter, as a model system for histiocytic disorders such
as severe forms of multisystemic Langerhans cells histiocytosis
(Steiner et al., 2008). These mice indeed display DC tumorigenesis,
mainly in the spleen and liver, which affects in particular the
CD8α cDC subset. In addition to the relevance to histiocytosis,
using this model, it has been possible to derive several murine
DC lines, originating from CD8α DC tumors primarily in spleen
(therefore termed MutuDC for “murine tumor”). Importantly,
DC tumor cells are not indefinitely viable directly ex vivo but can
undergo immortalization in vitro. We now present the derivation
procedure used to generate these immortalized MutuDC lines,
followed by their thorough characterization by direct compar-
ison to WT splenic cDC. We validate that MutuDC lines have
retained the major features characteristic of their natural counter-
part, the normal CD8α cDC subset. These include the response
to particular TLR-Ls such as CpG (TLR9-L) and PolyIC (TLR3-
L) but not R-848 (TLR7-L), IL-12 secretion and antigen cross-
presentation capacity. We furthermore show that the MutuDC
lines may be modified by lentiviral transduction or by crossing the
CD11c:SV40LgT-transgenic mice to the genetic background of
interest to obtain genetically modified MutuDC lines. Finally, we
discuss that the ease of culture and manipulation of the MutuDC
lines render them a potent auxiliary tool to support advances in
DC research.
MATERIALS AND METHODS
MICE AND TREATMENTS
The MutuDC lines derived are listed in Table 1 and originated
from spleen tumors in CD11c:SV40LgT-transgenic C57BL/6 mice
(Steiner et al., 2008). Other mice used were females or males at least
8 weeks old and were WT (C57BL6), Rag2−/−γc−/− (Mazurier
et al., 1999), MHC-I-deficient Bm1 mutant (B6.C-H2bm−1; Wil-
son et al., 2006; Lin et al., 2008), and the TCR-transgenic OT-1
Rag2−/−, OT-2, and T1 mice.
MUTU DC LINES
The DC lines are named after “murine tumor” (Mutu) followed
by the number of the mouse they originate from and the genetic
modification if applicable.
Culture conditions
The cell lines were derived and kept in culture at 37˚C in a humidi-
fied incubator with 5% CO2. The complete medium composition
was IMDM-glutamax (GIBCO 31980) adjusted with NaHCO3
to 310 mOsm if required and supplemented with 8–10% heat
inactivated FCS (tested for endotoxin toxicity toward DC cul-
tures), 10 mM Hepes (GIBCO 15630), 50µM β-mercaptoethanol
(GIBCO 31350), and 50 U/mL of penicillin and 50µg/mL strepto-
mycin (GIBCO 15070). The medium was not supplemented with
additional growth factors. MutuDC line cells were harvested by
incubation in non-enzymatic, 5 mM EDTA-based cell dissociation
buffer (5 mM EDTA in 20 mM Hepes-PBS).
Derivation method and maintenance
Figure 1 shows the standard procedure of MutuDC line deriva-
tion. Obtained from tumor-burdened animals, total splenocytes
including tumoral DC are seeded in serial dilutions starting at
high densities (>20× 106 cells per mL) in complete medium. The
proportion of DC in tumors is variable, ranging from 10 to 50%
of transformed CD8α DC. While the majority of cells (includ-
ing DC) will die in culture, groups of adherent DC slowly appear
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Table 1 | List of MutuDC line types currently available or in the process of being generated (“in progress”).
MutuDC line DC type Origin (mouse) Insert (lentivirus) Status (reference)
Genotype Background
WT CD8α+ CD11c:LgT-transgenic and
otherwise WT (Steiner et al., 2008)
C57BL6 Available (Fuertes
Marraco et al., 2011)
1IFNR−/− CD8α+ CD11c:LgT-Tg× Ifnar1(tm1.Agt) C57BL6 Available (Fuertes
Marraco et al., 2011)
TLR3−/− CD8α+ CD11c:LgT-Tg×Tlr3(tm1.Flv) C57BL6 Available (Fuertes
Marraco et al., 2011)
TLR9−/− CD8α+ CD11c:LgT-Tg×Tlr9(tm1.Aki) C57BL6 Available
MAVS−/− CD8α+ CD11c:LgT-Tg×CARDIF604Siec C57BL6 Available (Fuertes
Marraco et al., 2011)
NOX2−/− CD8α+ CD11c:LgT-Tg×Cybb (tm1.Din) C57BL6 Available
NIK−/− CD8α+ CD11c:LgT-Tg×Map3k14(aly) C57BL6 Available
H-2g7 (NOD) CD8α+ CD11c:LgT-Tg×NOD (Shi.Ltj)
back-cross
NOD Available
H-2d CD8α+ CD11c:LgT-Tg×Balb/c back-cross BALB/c In progress
H-2k CD8α+ CD11c:LgT-Tg×C3H back-cross C3H In progress
Kb−/− CD8α+ CD11c:LgT-Tg×H–2Kb (tm1) C57BL6 In progress
IRF8−/− CD8α− (CD11b+) CD11c:LgT-Tg× Irf8(tm1.Hor) C57BL6 Available
BATF3−/− CD8α− CD11c:LgT-Tg×Batf (tm1.1Kmm) C57BL6 In progress
Langerin:Tg CD8α+ Langerin:LgT-Tg and otherwise WT C57BL6 In progress
CD80/CD86 −/− CD8α+ CD11c:LgT-
Tg×CD80−/−×CD86−/−
C57BL6 In progress
Bim−/− CD8α+ CD11c:LgT-Tg×Bcl2l11(tm1.1Ast) C57BL6 Available
Bid−/− CD8α+ CD11c:LgT-Tg×Bid (tm1.1Ast) C57BL6 In progress
Noxa−/− CD8α+ CD11c:LgT-Tg×Pmaip1(tm1.1Ast) C57BL6 In progress
Bim−/− Bid−/− CD8α+ CD11c:LgT-
Tg×Bcl2l11(tm1.1Ast)×Bid
(tm1.1Ast)
C57BL6 In progress
Bim−/− Noxa−/− CD8α+ CD11c:LgT-
Tg×Bcl2l11(tm1.1Ast)
×Pmaip1(tm1.1Ast)
C57BL6 In progress
Caspase-1−/− CD8α+ CD11c:LgT-Tg x Caspase-1−/− C57BL6 In progress
IFNβ+ 1IFNR−/− CD8α+ CMV:IFNβ+;
CD11c:LgT-Tg× Ifnar1(tm1.Agt)
C57BL6 IFNβ (NM_010510) Available
Luciferase+ CD8α+ CMV:Luciferase+; CD11c:LgT-Tg C57BL6 Luciferase (AB261982) Available
Indo+ CD8α+ CMV:Indo+; CD11c:LgT-Tg C57BL6 IDO (NM_008324.1) In progress
Arginase+ CD8α+ CMV:Arginase+; CD11c:LgT-Tg C57BL6 Arginase (NM_007482.2) In progress
IL-10+ CD8α+ CMV:IL-10+; CD11c:LgT-Tg C57BL6 IL-10 (NM_010548.1) In progress
latent TGFβ+ CD8α+ CMV:latentTGFβ+; CD11c:LgT-Tg C57BL6 latent TGFβ (NM_011577.1) In progress
active TGFβ+ CD8α+ CMV:activeTGFβ+; CD11c:LgT-Tg C57BL6 active TGFβ (mutant Cys223 and 225;
Fowlis et al., 1996)
In progress
Activin A+ CD8α+ CMV:ActivinA+; CD11c:LgT-Tg C57BL6 Activin A (NM_002192)
CTLA-4+ CD8α+ CMV:CTLA-4+; CD11c:LgT-Tg C57BL6 CTLA-4 (NM_009843) In progress
B7-H1/PDL1+ CD8α+ CMV:B7-H1+; CD11c:LgT-Tg C57BL6 B7-H1 (NM_021893) In progress
B7-DC/PDL2+ CD8α+ CMV:B7-DC+; CD11c:LgT-Tg C57BL6 B7-DC (NM_021396) In progress
IL-2+ CD8α+ CMV:IL-2+ CD11c:LgT-Tg C57BL6 Il-2 (NM 008366) In progress
IL12+ CD8α+ CMV:IL-12+ α and β as single chain
construct with linker; CD11c:LgT-Tg
C57BL6 IL12α and β Fc (NM_001159424)
(NM 008352)
In progress
IL35+ CD8α+ CMV:IL-12α and CMV:EBI3+ as
single chain construct with linker;
CD11c:LgT-Tg
C57BL6 IL-12α and EBI3 (NM 015766) In progress
IL-15+ CD8α+ CMV:IL-15+; CD11c:LgT-Tg C57BL6 IL-15 (NM 008357) In progress
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DC line derivation 
1. Mesh tumor through a 40 um cell strainer with medium and wash cells.
2. Seed cells in 24-well plates, at >50 million cells / ml in first well (1ml/well) then 
    serially dilute 1/3 in 5 other wells. Prepare multiple serial dilutions.
3. After at least 24h (adherent cells attach), change medium periodically, removing 
    non-adherent cells and debris, until a layer of DC is clearly visible.
4. Progressively split* into well with larger surface and finally into 25cm2 flasks. Split
only when cultures reach confluency, otherwise, refresh medium only.
5. Split flasks intially at 1/2, then gradually increase dilution according to the fitness
    of the cells. By p10**, DC lines are readily used, endure 1/10 splitting and vials can 
    be stored frozen.
* To detach cells, remove SN and incubate in 5mM EDTA-PBS (non-enzymatic).
** Time to p10 is variable: ranges from 10-25 weeks.
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FIGURE 1 | Derivation of MutuDC lines. (A) Schematic diagram and
procedure for the derivation of MutuDC lines (NB. “p” followed by a number
designates “passage”). (B) The number of cell divisions during 1 week is
shown for eight different cell lines at different passages (n=3 for passages
5–10, n=5 for passage >15), based on trypan blue counts of MutuDC line
cultures starting at 5×104 cells per 0.5 mL per cm2. (C) The growth of one
representative MutuDC line as a function of cell density is shown, measured
by thymidine incorporation (n=3) by seeding MutuDC line cells in flat-bottom
96-well plates at the indicated densities and adding 0.5µCi of 3H-thymidine
per well for 15 h. Data are presented as mean±SD.
in the cultures (Figure 2). Selection of the latter and removal
of dead cells is allowed by periodic change of medium, until a
monolayer of DC is clearly visible. Early passages are split at a
maximum 1:2 dilution, and the dilution is progressively increased
with passage. As a standard, MutuDC lines that reach passage 10
are normally capable of cell division at least once every 1.5 days
(Figure 1B) and can be readily used. The derivation process up
to passage 10 may last from 2 months to over half a year, but
most MutuDC lines have been derived within 4 months. Estab-
lished MutuDC lines (from passage 5 to 10 onward) are passaged
by splitting at 1:10–1:15 from confluency, and re-seeded not lower
than 25,000 cells per cm2 (Figure 1B). MutuDC lines can be kept
in liquid nitrogen stocks (frozen at a density of 2–3 million per mL
in 50% FCS and 10% DMSO in complete medium) and endure
well such cryo-preservation. Use of the cells at passages higher
than 50 is generally not recommended, as we have observed a clear
decrease in their response and cytokine producing capacity above
70 passages (Figure A6 in Appendix). Of note, CD11c:LgT-Tg
mice may develop DC tumors elsewhere than in spleen. The same
DC line derivation procedure can be performed from DC tumors
in thymus, liver, bone marrow, and lymph nodes (e.g., mesen-
teric and inguinal lymph nodes). Technically important to keep
in mind, MutuDC lines are GFP positive due to the GFP reporter
in the CD11c:SV40LgT transgene. Table 1 lists all the types of
MutuDC lines that are currently available or in the process of being
generated (“in progress”). The majority of experiments were
done on the WT DC lines “MutuDC1940”, “MutuDC4525”,
“MutuDC1995”, “MutuDC2069” and “MutuDC2114”. DC lines
lacking genes of interest (“MutuDCIfnar1−/−”,“MutuDCTlr3−/−”
and “MutuDCTlr9−/−”) were generated by crossing the
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FIGURE 2 | Morphology of MutuDC line cultures. (A,B). Light microscopy
images of five representative MutuDC lines at early [(A), MutuDC line 4417]
or later passages [(B), MutuDC lines as indicated]. MutuDC lines may show
different morphologies (in (B)], e.g., MutuDC1940 tends to show more
aggregates and MutuDC2069 presents less dendrites. Moreover, these
traits tend to be more pronounced in all cell lines with longer times of
culture without splitting or harvest. (C,D) Immunofluorescence microscopy
of one representative DC line (MutuDC2114) showing CD11c [in red, in (C)]
and MHC-II [in yellow, in (D)]. Nuclei were stained with DAPI.
CD11c:SV40LgT-Tg mice (Steiner et al., 2008) to the relevant
gene-targeted mice (Table 1).
SPLENIC cDC SUBSET PURIFICATION
Spleens were chopped and digested for 30 min at 25˚C with
collagenase D (1 mg/mL) and DNAse I (40µg/mL) in RPMI-
1640 complemented with 3% FCS, with occasional gentle mix-
ing in order to extract and preserve maximal numbers of
DCs. Cell suspensions were passed through 40µm sieves and
washed in PBS containing 5 mM EDTA and 5µg/mL DNAse I
and then resuspended in PBS containing 5 mM EDTA and 3%
FCS. Total splenocytes were fractionated by density centrifuga-
tion in isohexol carbohydrate medium (Nycodenz, Axis-Shield,
Norway) at 1.077 g/cm3 (Naik et al., 2006). The DC-enriched,
light density fraction was collected and washed in PBS con-
taining 5 mM EDTA prior to CD11chigh DC enrichment using
anti-CD11c antibody-coupled magnetic micro-beads (Miltenyi
Biotech). Alternatively, for proteomic experiments, CD8α+ cDCs
were isolated as described previously (Luber et al., 2010). The
cDCs represent 1–2% of total splenocytes. Within the cDC pop-
ulation, typically ∼20% were CD8α cDCs and ∼60% CD11b
cDCs. Density centrifugation allowed for a ∼10-fold enrich-
ment in DCs prior to immunomagnetic bead selection. Enriched
DC preparations used for flow cytometry cell sorting contained
more than 85% cDCs, and resulting cDC subsets were purified
to at least 95%. At least 10 mice were required to isolate 106
viable CD8α+ cDCs and 2.5 mice to isolate 106 CD8α− cDCs
(Figure 3).
TREATMENTS IN VITRO
Dendritic cells stimulations were performed using PolyIC
(5µg/mL, Invivogen), CpG (2 mM, TriLink), R-848 (1µg/mL,
Invivogen), and LPS (5µg/mL, Ultra-pure, Invivogen). Cross-
linking CD40 antibody (clone FGK45, Miltenyi Biotech) was used
at 10µg/mL. IFNγ was used at 100 U/mL.
MICROSCOPY
Light microscopy
Cell cultures were directly photographed using the Leica Firecam
3.2 software on Leica DM IL LED microscope equipped with a
Leica DFC295 camera.
Confocal microscopy
MutuDC lines were labeled with fluorochome-conjugated CD11c
(clone N418,APC, Biolegend) and MHC-II (clone M5,APC, Biole-
gend). MutuDC lines were seeded on Poly l-lysine-coated slides
overnight, fixed with 4% paraformaldehyde for 15 min at RT,
and stained for 30 min at 4˚C before mounting for fluorescence
microscopy.
FLOW CYTOMETRY
The fluorochrome-conjugated antibodies used were specific to
CD11c (clone N418, PECy7, eBioscience), CD45R-B220 (clone
RA3-6B2, eF450, BioLegend), GR1 (clone RB6-8C5, PE, BioLe-
gend, or PerCP-PECy5.5, eBioscience), CD8α (clone 54-6.7, FITC,
eBioscience or APC-Cy7, BioLegend), DEC205 (clone 205yekta,
PerCP-eF710, eBioscience), CD24 (clone M1/69, PerCP-Cy5.5,
eBioscience), Clec9A (clone 42D2, PE, eBioscience), CD11b
(clone M1/70, APC, eBioscience), SIRPα (CD172, clone p84,
APC, Becton Dickinson), CD4 (clone RM4-5, APC, eBioscience),
MHC-I (clone AF6-88.5.5.3, APC, eBioscience), MHC-II (clone
M5/114.15.2, PE, Pharmingen), CD40 (clone 1C10, APC, eBio-
science), CD80 (clone 16-10A1, PECy5, eBioscience), CD86
(clone GL1, APC, eBioscience, or Alexa750, BioLegend), and Va2
(B20.1, PE, eBioscience). Flow cytometric analyses were per-
formed with FACScan, FACSCanto, or LSR II cytometers (Bec-
ton Dickinson) using FACSDiva (version 6.1.3, Becton Dickin-
son) and FlowJo (Version 9, Tree Star, Inc.) softwares for data
processing.
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FIGURE 3 | Purification method and yields for the isolation of normal
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GENE EXPRESSION ANALYSES
RNA isolation and cDNA synthesis
Total RNA was isolated from MutuDC line samples and purified
splenic cDC subsets using the spin columns from Qiagen RNeasy®
following the manufacturer’s protocol, with DNAse I digestion
on-column and elution in 5µL of RNAse-free water. Total RNA
yields were quantified by Nanodrop spectrophotometry (Thermo
Fisher Scientific, Inc.). The average yield was 5µg/106 cells for
MutuDC lines and 200 ng/106 cells for freshly isolated splenic sub-
sets. Synthesis of cDNA was performed using random non-amer
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primers and the Superscript II Reverse Transcriptase kit (Invitro-
gen) starting from 0.2 to 1µg of total RNA. Cleanup of cDNA
was performed using spin columns from Wizard SV Gel and PCR
cleanup (Promega), eluting cDNA in 50µL of RNAse-free water
and quantifying yield by Nanodrop as above. Samples were diluted
at 3 ng/µL for Q-RT-PCR or at 50 ng/µL for semi-quantitative
PCR, using 2µL per PCR reaction (5 and 10µL final volume,
respectively).
Quantitative real-time PCR analysis
Quantitative real-time PCR (qRT-PCR) was performed using
SYBR Green mix on LightCycler (capillary, 10µL reaction) or
LighCycler480 (384-well plate, 5µL reaction) from Roche Diag-
nostics. The primers used for Tlr3 and for Tlr7 expression were
as previously described (Edwards et al., 2003). Relative expres-
sion levels were analyzed using second derivative method with LC
data analysis 3.5 Software (Roche). The housekeeping gene used
was TBP. QRT-PCR was performed with at least technical dupli-
cates. For the analysis, expression of each gene was normalized
to the housekeeping gene, generating a single value per biological
replicate.
Nanostring technology
Stimulations were performed in duplicate, using 500,000 cells per
sample. Supernatants were collected for ELISA quantifications of
IL12p40 and IL12p70 to confirm efficient activation (data not
shown) while cells were collected for mRNA analyses using Nanos-
tring technology. Cell lysis and RNA extraction were performed
using spin columns from Qiagen RNeasy® following the manu-
facturer’s protocol. RNA quality was controlled using an Agilent
2100 bioanalyzer and only samples showing minimal degradation
(RIN> 8) were kept. RNA probes were ordered from NanoS-
tring® Technologies and controlled for gene sequence specificity
before use by qRT-PCR (data not shown). Hybridization and
quantification was done according to the manufacturer’s proto-
col and quantification and normalization was performed using
an in-house developed program running in a Microsoft Excel
environment developed at the University of Geneva’s Genomics
Platform.
CYTOKINE SECRETION
Supernatants were assayed for IL-12 production by ELISA using
the IL-12p40 and IL-12p70 kits from BD Biosciences according
to the manufacturer’s protocol, except that the assay diluent was
composed of 1% BSA and 10% FCS in PBS.
ANTIGEN PRESENTATION ASSAYS
Untouched OT-I CD8 T cells and OT-II CD4 T cells were
purified from TCR-transgenic mice (OT-I and OT-II, respec-
tively) by negative selection using immunomagnetic beads (Mil-
tenyi Biotech). For direct MHC-I or MHC-II antigen presenta-
tion assays, MutuDC lines or freshly isolated DC were seeded
at 10,000 cells per well in round-bottom 96-well plates. For
MHC-I-restricted antigen presentation assays, DC were incubated
for 2 h with SIINFEKL (OVA257–264) at the indicated concentra-
tions, washed three times in medium, irradiated at 40 Gy, and
incubated with 50,000 purified OT-I CD8 T cells (eFluor670-
labeled). Similarly, for MHC-II-restricted antigen presentation,
DC were pre-incubated for 2 h with OVA323–339 peptide, irradi-
ated at 40 Gy, and incubated with 50,000 purified OT-II CD4 T
cells (eFluor670-labeled). For cross-presentation of cell-associated
antigen, MutuDC lines or freshly isolated DC were seeded at
25,000 cells per well in V-bottom 96-well plates, incubated with
the indicated numbers of OVA-coated splenocytes (OCS, prepared
from MHC-I-mutant Bm1 mice as previously described; Wil-
son et al., 2006), irradiated at 40 Gy, and incubated with 50,000
purified OT-I CD8 T cells (CFSE-labeled). T cell proliferation
was measured after 60 h of culture by flow cytometry analy-
sis excluding doublets and dead cells. OT-II CD4 T cells were
gated as CD4+ Vα2+ cells and OT-I CD8 T cells were gated
as CD8+ Vα2+ cells. Live dividing T cells were detected as low
for cell proliferation dyes (eFluor670 low or CFSE low as indi-
cated) and quantitated using calibration particles (BD Biosciences
Pharmingen).
For H-2Kd-restricted antigen presentation by MutuDC lines
that were lentivirally transduced with H-2Kd, the system used
was the Plasmodium Berghei circumsporozoite (PbCs) pep-
tide 252–260 (SYIPSAEKI) and the cognate T1 TCR-transgenic
CD8 T cells as previously described (Segura et al., 2008). In
round-bottom 96-well plates, 3,000 K d-positive or untransduced
MutuDC line cells were seeded and pulsed with titrating con-
centrations of PbCs252–260 peptide for 2 h, washed three times
in medium, irradiated with 40 Gy, and co-cultured with 10,000
CD8 T cells isolated from T1 TCR-transgenic mice (DC:T cell
ratio= 1:3). Proliferation measured at day 3 by 3(H)-thymidine
incorporation adding 0.5µCi per well for the last 15 h of
culture.
LENTIVIRAL TRANSDUCTION AND TRANSFECTION IN MutuDC LINES
Second generation lentiviral plasmids used were (pWP-SIN-cPPT-
WPRE)-CMV-IRES-GFP lentiviral vector and the two packaging
plasmids pMD2G and psPAX2. The lentiviral system and proto-
cols have been described elsewhere (Salmon and Trono, 2007).
Inserts (Table 1) were obtained by PCR amplification of cDNA
from MutuDC line samples or splenocytes. Transduction was done
into MutuDC lines, performing either mock (CMV:GFP; control)
or specific (CMV:insert:GFP) transductions. The multiplicity of
infection (MOI) used was between 5 and 10. Expression of the
transgene began around day 4 post-transduction. As MutuDC
lines already express GFP, only a shift in GFP was observed after
transduction with GFP reporter-encoding transgenes. Efficiency
of transduction was measured by FACS and WB for cellular pro-
teins or ELISA for secreted proteins. For the representative lentivi-
ral transduction shown in Figure 9A, the DC line “MutuDC1715
II” was transduced with H-2Kd as previously described (Segura
et al., 2008). Table 1 lists other MutuDC lines modified by lentivi-
ral transduction. Transfection with pDsRedExpress plasmid DNA
(Clontech) was performed using the JetPEI solution (Chemie
Brunschwig AG) according to the manufacturer’s manual or by
a standard calcium phosphate transfection method. Electropora-
tion was performed to transfect the pmaxGFP (Amaxa biosystems)
with either Solution L or Solution V (Amaxa biosystems, Lonza)
using the Amaxa Nucleofactor II device. pmaxGFP expression
was distinguished from the endogeneous GFP by a shift in GFP
expression level.
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STATISTICAL ANALYSES
Statistical analyses were performed using GraphPad Software
Inc. Where indicated, p-values were obtained using two-tailed
unpaired t -tests with 95% confidence intervals (ns= not sig-
nificant; ∗= p< 0.05; ∗∗= p< 0.01; ∗∗∗= p< 0.001); Spearman’s
rank correlation coefficients indicate 1= perfect correlation,
0= no correlation,−1= perfect reverse correlation; Best-fit slope
values were obtained by non-linear regressions using the robust fit
method. Where shown, error bars indicate standard deviations.
RESULTS
DERIVATION AND MAINTENANCE OF MutuDC LINES
MutuDC lines are derived from CD8α+ DC tumors that develop
in the previously described CD11c:SV40LgT-transgenic mice
(Steiner et al., 2008). The derivation of MutuDC lines is based
on the stabilization and growth of tumoral DC in culture, once
transformation driven by the SV40 LgT oncogene has taken place
in vivo. Figure 1 shows a diagram of the standard procedure for the
derivation of MutuDC lines, further described in detail in Mate-
rials and Methods. Importantly, immortalization in vitro occurs
“spontaneously” in standard complete medium, in absence of
additional growth factors and with minimal manipulation. Result-
ing MutuDC lines may display different morphologies, ranging
from growth exclusively in monolayers to a propensity to aggre-
gate (Figure 2). This aggregation can be lost at later passages. As
detailed in Section “Materials and Methods,” MutuDC lines from
passage 10 onward divide at least once every 1.5 days (Figure 1B),
can be stored frozen with optimal recovery upon thawing, and
are easily maintained by standard cell culture practice. Growth is
most efficient at a density of 2.5× 105 cells per cm2 (Figure 1C).
For optimal maintenance, MutuDC line cultures should not be
split lower than 5× 104 cells per cm2 (e.g., 106 cells in one 25 cm2
flask). For standard experiments, MutuDC line cells are seeded at
around 105 cells per cm2, with variation depending on the kinet-
ics of the experiment and considering the confluency at around
5× 105 cells per cm2.
MutuDC LINES VERSUS PURIFIED SPLENIC cDC EX VIVO
In this study, we directly compared the MutuDC lines to splenic
cDC ex vivo, in particular to their natural counterpart of origin,
the CD8α+ cDC subset. It is important to note the technical dif-
ficulty that represents obtaining highly pure splenic cDC samples,
and the limited viability of splenic cDC ex vivo. DC represent a
minor fraction of immune cells, for example, out of a 100 million
cells that can be easily recovered from a standard mouse spleen, as
little as 2–3% are cDC (CD11c+B220−), of which typically 25%
belong to the CD8α subtype (standard: 1 million spleen CD8α+
DC per mouse spleen). For our experiments, splenic cDC subsets
were isolated by gentle collagenase digestion, followed by progres-
sive enrichment in three steps (Figure 3): (1) Density gradient
centrifugation to obtain a DC-rich fraction; (2) immunomagnetic
bead-based enrichment of CD11c+ cells to purify cDC; and (3)
flow cytometry-based cell sorting of cDC into highly purified cDC
subsets (CD8α+ or CD8α−). An average of 200,000 CD8α+ and
900,000 CD8α− (CD11b+) cDC could be recovered per spleen. Of
note, due to stress, close to half of splenic cDC are lost immedi-
ately after flow cytometry sorting. Overall, this procedure allowed
to minimize both costs and time, reducing cellular stress and opti-
mizing survival of splenic cDC ex vivo, with DC yields in the
expected range (Figure 3; Inaba et al., 2009).
Importantly, major advantages of MutuDC lines are their ease
of maintenance in culture and expansion, being an unlimited and
immediate source of material, as well as their high viability, as
compared to the technical difficulties, workload and experimental
limitations in using normal splenic cDC ex vivo.
THE MutuDC LINES SHARE CHARACTERISTIC SURFACE MARKERS AND
PROTEOME PROFILE WITH SPLENIC CD8α cDC
The MutuDC lines derived were assessed for the expression of a
panel of surface markers most commonly used to categorize DC
subsets (Villadangos and Schnorrer, 2007), by direct comparison
to normal WT splenic cDC subsets (Figure 4). These included
markers characteristic of splenic CD8α+ cDC such as the endo-
cytic receptor DEC205 and CD24 (Martinez del Hoyo et al., 2002;
Naik et al., 2006) as well as the more recently discovered marker
Clec9A (Caminschi et al., 2008; Huysamen et al., 2008; Sancho
et al., 2008). Conversely, markers characteristic of CD8α− cDC
included CD11b, CD172, and CD4. Several of these markers were
also assessed at the mRNA level, in parallel with the transcription
factors IRF8 and IRF4 involved in CD8α+ and CD8α− cDC subset
development, respectively (Figure A1 in Appendix).
As shown in Figure 4, MutuDC lines show surface mark-
ers of cDC: CD11chigh B220− GR1− and MHC-II+. Impor-
tantly, MutuDC lines closely resembled the CD8α+ subset and
were positive for DEC205, CD24, and Clec9A while negative for
CD4 and CD172 (Figure 4; Figure A1 in Appendix). At the
mRNA level, MutuDC lines showed the differentially high expres-
sion of IRF8 and low expression of IRF4 characteristic of the
CD8α+ cDC subset (Figure A1 in Appendix). Notably, different
MutuDC lines showed variability in CD8α and CD11b levels, in
some cases showing downregulation of CD8α and upregulation
of CD11b as compared to splenic CD8α+ cDC (Figures 4B,C;
Figure A1 in Appendix). This is possibly due to cell culture
conditions, as MutuDC lines could regain CD8α expression and
downregulate CD11b upon adoptive transfer in vivo (Figure A2
in Appendix). Pertinently, lack of CD8α expression has been
observed in the BM-DC culture system, where CD24 or SIRPa
are used as surrogate markers to identify CD8α+ or CD8α−
DC equivalents, respectively (Naik et al., 2005). In addition,
while the function of CD8α and CD11b in DC is not known,
human DC do not express CD8α and the equivalent of mouse
splenic CD8α+ cDC has been recently identified as Clec9a+
DC in humans (Poulin et al., 2010; Villadangos and Shortman,
2010).
Overall, the pattern of surface markers in MutuDC lines closely
correlated with splenic CD8α+, with a Spearman rank correlation
coefficient of 0.811 comparing MutuDC lines and splenic CD8α+
cDC, versus 0.256 comparing MutuDC lines and splenic CD8α−
cDC (Figure 4D).
Next, we compared freshly isolated CD8α+ DC from mouse
spleens to our DC cell line on the proteome level. To achieve
highest possible quantitation accuracy, we labeled MutuDC1940
cells with stable isotopes using SILAC and spiked it into ex vivo
isolated CD8α+ DCs. Duplicate analysis revealed an unimodal
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with the splenic CD8α+ cDC subset. (A) Gating strategy for the flow
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histograms show one representative sample for splenic cDC in parallel to five
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MutuDC1940, MutuDC2069, MutuDC2114, MutuDC1995). Histograms of
total splenocytes are also shown as staining controls. In (C), the geometric
MFI is shown for the different surface markers as indicated for splenic cDC
subsets (n=2) and MutuDC lines (n= 5). Data are presented as mean±SD.
(D) Scatter plot and Spearman’s rank correlation coefficients based on the
data shown in (B). The scatter plot shows the average geometric MFI value of
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DC types is shown.
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distribution of ratios with 90% of the quantified proteins within
a 2.1-fold expression difference between the MutuDC1940 and
the ex vivo isolated CD8α+ cells (Figure A3 in Appendix, Pro-
teomics.xls). These results indicate that the expression patterns of
MutuDC lines and ex vivo isolated CD8α+ are very similar making
the former an appropriate in vitro counterpart of CD8α+ DCs.
THE MutuDC LINES HAVE RETAINED THE FUNCTIONAL
CHARACTERISTICS OF WILD TYPE SPLENIC CD8α cDC
It was critical to assess if the MutuDC lines retained the major
functional properties characteristic of splenic CD8α+ cDC. Com-
pared to the CD8α− subset, CD8α+ DC express higher levels of
TLR3 and lack TLR7 expression (Edwards et al., 2003; Luber et al.,
2010). In response to PAMP stimulation, CD8α+ DC are particu-
larly capable of producing Th1 cytokines such as IL-12. Further-
more, distinct antigen presentation capacities have been attributed
to different DC subsets, with CD8α+ DC being uniquely capable
of antigen cross-presentation (Hildner et al., 2008). Altogether,
CD8α+ DC are critical inducers of Th1 and CTL responses.
In order to assess the functional competence of MutuDC
lines, normal WT splenic CD8α+ or CD8α− cDC subsets were
freshly purified and compared to MutuDC lines in the following
functional assays in vitro.
MutuDC lines respond to TLR3 but not TLR7 stimuli
Similar to splenic CD8+ cDC, the MutuDC lines expressed TLR3,
TLR4, and TLR9, while showed no expression of TLR7, which
was only detectable in CD8α− cDC (Figure 5; Edwards et al.,
2003). Accordingly, upon stimulation with the respective TLR-Ls
in vitro, MutuDC lines strongly responded to PolyIC (TLR3-
L), CpG (TLR9-L), and to a lesser extent to LPS (TLR4-L), by
upregulation of co-stimulatory molecules CD40, CD80, and CD86
(Figure 6). Conversely, MutuDC lines showed no response to R-
848 (TLR7-L). Such profile of TLR-L response in MutuDC lines
corresponded to the responses observed in wild type CD8α+ cDC,
and contrasted with the generally weaker activation in CD8− DC,
as supported by the higher Spearman rank correlation coefficients
between MutuDC lines and CD8α+ cDC as compared to MutuDC
lines versus CD8α− cDC. The latter uniquely responded to TLR7-
L by CD40 upregulation (Edwards et al., 2003). In response to
TLR-Ls, the MutuDC lines also upregulated the activation marker
CD70 (data not shown).
MutuDC lines efficiently produce the Th1-inducing cytokine IL-12 in
synergistic response to TLR-Ls, IFNγ, and anti-CD40 stimuli
IL-12 production is one of the major features of splenic CD8α
cDC (Hochrein et al., 2001), with its consequent Th1-polarizing
and CTL-inducing function. Multiple signals are however required
to fully activate IL12 production in DC, with particular combina-
tions and time-points of stimulation resulting in different extents
of IL-12 secretion (Macagno et al., 2007). For instance, microbial
stimulation primes DC for subsequent CD40-induced IL-12 pro-
duction (Schulz et al., 2000), in line with the synergies that have
been observed amongst CD40, cytokine, and TLR stimulations
(Snijders et al., 1998; Bosisio et al., 2002; Napolitani et al., 2005).
In order to assess the capacity of MutuDC lines to produce
cytokines, MutuDC lines and purified wild type splenic cDC sub-
sets were stimulated with several combinations of TLR-Ls (CpG
and/or PolyIC), IFN-g and cross-linking anti-CD40 antibody were
assayed for IL-6 and IL-12 (p40 and p70) secretion (Figure 7A).
TLR-Ls alone could induce substantial secretion of IL-12 p40 in
both MutuDC lines and splenic CD8α+ DC, while CD8α− DC
secreted lower amounts of p40. For secretion of the bioactive
IL-12 p70 subunit, TLR-Ls displayed synergy with IFNγ and anti-
CD40. Importantly, the MutuDC lines were capable of efficient
IL-12p40/p70 secretion in a manner comparable or higher than
the freshly isolated CD8α+ cDC counterpart, while CD8α− cDC
produced low levels of IL-12p70 only with the full combination
of stimuli. A similar secretion profile was observed for IL-6, with
MutuDC lines and CD8α+ DC producing higher amounts and
displaying synergy amongst treatments, in contrast to the poor
induction of IL-6 in CD8α− DC (data not shown).
Taking advantage of the easy access to large numbers of cells
and their fitness in culture, the MutuDC lines were used to
perform large-scale mRNA analysis upon numerous stimulations
using Nanostring technology. Similarly to the experiments above,
MutuDC lines were stimulated with different combinations of
PolyIC, CpG, IFNγ, and anti-CD40 for 20 h (Figure 7B). A total
of 188 genes were analyzed, of which 16 showed clear synergistic
effects in mRNA upregulation upon treatment with different
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FIGURE 7 | MutuDC lines efficiently produce IL-12 p70 and show
synergism in response to different combinations ofTLR-Ls, IFNγ and
aCD40. (A) DC lines (n=4) and purified splenic cDC subsets (n=2 per
subset) were stimulated with different combinations of TLR-Ls (CpG,
PolyIC), IFNγ, and cross-linking anti-CD40, as indicated. The supernatants
were collected after 15 h and analyzed for IL-12 p40 and p70 secretion by
ELISA. Data are presented as mean±SD, with the corresponding
Spearman’s rank correlation (and its p-value) coefficient comparing all
three types of DC. (B) MutuDC lines (n=3) were stimulated for 20 h with
different combinations of TLR-Ls (CpG or PolyIC), IFNγ, and cross-linking
anti-CD40, as indicated, and mRNA expression was quantified by
Nanostring technology. Genes shown in the heat map displayed a clear
synergistic effect upon stimulation with multiple agents (green: low
expression, to red: high expression). For each gene, a value for the
synergistic increase is given (right side of the gene row) based on the fold
increase in the stimulation with the full combination of reagents (CpG,
PolyIC, IFNγ, and aCD40) versus the sum of stimulations with each
reagent individually (Equation= value for “CpG, PolyIC, IFNγ, aCD40”
divided by the sum of values for “CpG”+“PolyIC”+ IFNγ+“aCD40,”
with background subtraction for each value). (C) Impact of the lack of
1IFNR on mRNA expression of several genes upon stimulation. DC lines
genetically deficient for the 1IFNR (n=2 per treatment; derived from DC
tumors in 1IFNR−/− mice) were stimulated and analyzed as in, (B)
compared to WT MutuDC lines. The gene expression data for eight
representative genes upon stimulation in WT versus 1IFNR−/− DC lines are
shown in more detail in Figure A5 in Appendix.
combinations of stimuli as compared to individual stimulations.
As expected, these genes included Il6 and Il12p40, in agreement
with the experiments above.
Interestingly, other genes showing synergy were Ccr7, Pdl1
(B7h1), Pdl2 (B7dc), Cxcl1, Indo, and Il2. The complete
list of the 188 genes and mRNA expression upon stimula-
tion is accessible as supplemental data (Nanostring.xls). Using
ELISA and Luminex analyses, MutuDC lines also secreted
IL-1α and β, IL-2, IL-10, TNFα, CCL3/MIP-1α, CCL4/MIP-
1β, CCL5/RANTES, CXCL2/MIP-2, CXCL3/KC, CXCL9/MIG,
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CXCL10/IP10, CXCL11//I-TAC, CX3CL1/Fractalkine similar to
their in vivo counterparts upon stimulation (data not shown).
The MutuDC lines are capable of MHC-I and MHC-II-restricted
antigen presentation, including cross-presentation
While both CD8α+ and CD11α− cDC subsets are capable of
antigen presentation, CD8α cDC are particularly capable of cross-
presentation of cell-associated antigens. Several antigen presenta-
tion modes were tested on MutuDC lines in comparison to normal
splenic subsets, using the OT-I or OT-II TCR-transgenic T cell sys-
tems, including cross-presentation of cell-associated OVA to OT-I
CD8 T cells (Wilson et al., 2006; Figure 8). While both splenic
subsets were capable of direct presentation in both the MHC-I-
restricted (SIINFEKL/OT-I) and the MHC-II-restricted (OVA323-
339/OT-II) systems, CD8α+ cDC were remarkably more capable
of antigen cross-presentation (Wilson et al., 2006; Figure 8). Albeit
to varying degrees, MutuDC lines were capable of antigen pre-
sentation in all three settings (Figure 8A). Best-fit slopes were
calculated to quantify the relative capacity to present antigen com-
paring the different DC types and, similar to splenic CD8α+ cDC,
the MutuDC lines were particularly superior at antigen cross-
presentation compared to CD8α− cDC (best-fit slop of at least
5; Figure 8B). These results show that antigen-presenting capacity
is preserved in MutuDC lines, notably the cross-presenting mode,
similarly to their CD8α cDC counterparts.
GENERATION OF MODIFIED MutuDC LINES
Lentiviral transduction of MutuDC lines
The possibility to genetically manipulate cell lines is an impor-
tant technical advantage. We tested several methods of gene
over-expression in MutuDC lines. Transfection methods included
the calcium phosphate-induced DNA precipitation method, the
JetPEI PolyPlus transfection (Chemie Brunschwig AG) solu-
tion, and several protocols and solutions for the electroporation
method (Amaxa biosystems, Lonza; Figure A4 in Appendix).
While MutuDC lines showed transgene expression upon trans-
fection using the calcium phosphate protocol and several elec-
troporation methods (Figures A4A,D in Appendix), transfection
activated the cells (Figure A4B in Appendix) and the viabil-
ity of the cultures was greatly affected (Figure A4D in Appen-
dix). Therefore, transfection methods only allowed short-time
experiments.
In contrast, MutuDC lines could be successfully modified by
lentiviral transduction. Figure 9A shows a representative exam-
ple where MutuDC lines (C57BL6 background, H–2Kb) could be
modified to express the H-2Kd molecule and efficiently presented
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FIGURE 8 | MutuDC lines are competent for MHC-I- and MHC-II-restricted
presentation toT cells, including cross-presentation, similarly to splenic
CD8α cDC. Two independent MutuDC lines (n=2 per line) were directly
compared to purified splenic cDC subsets for their capacity to present
antigen to T cells (A). Direct MHC-I-restricted antigen presentation: DC were
loaded with SIINFEKL peptide at the indicated concentrations and co-cultured
with OT-1-transgenic CD8 T cells. MHC-II-restricted antigen presentation: DC
were incubated with Ova323–339 peptide at the indicated concentrations and
co-cultured with OT-2-transgenic CD4 T cells. MHC-I-restricted
cross-presentation: DC were co-cultured with ovalbumin-coated splenocytes
(OCS) at the indicated numbers and further co-cultured with OT-1-transgenic
CD8 T cells. T cell proliferation was quantified at day 3. The experiments are
described in detail in Section “Materials and Methods.” Data are presented as
mean±SD (B). Values of the best-fit slope comparing each DC type
(“subject” column: MutuDC lines or splenic cDC subsets) to the splenic
CD8α+ or CD8α− cDC references (in columns, as indicated). The data from (A)
were analyzed by performing non-linear fit regressions (with robust fit) as a
measure of the relative magnitude of the response induced by different DC
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the K d-restricted peptide SIYPSAEKI to the cognate T1 TCR-Tg
CD8 T cells.
Genetically knock-out MutuDC lines
Potentially, MutuDC lines can be derived from any knock-out
or transgenic background of interest by crossing it with the
CD11c-SV40LgT mice. As an example, the MutuDCTlr9−/− and
MutuDCTlr3−/− DC lines were generated and as expected, did
not respond to CpG and PolyIC, respectively (Figures 9B,C). In
response to the relevant TLR-L, there is neither upregulation of
co-stimulatory molecules (CD40, CD80; Figure 9B) nor secretion
of IL-12 p40 (Figure 9C). Importantly, the synergies described
above in IL-12 p70 secretion by TLRs/IFNγ/anti-CD40 combi-
nations (Figure 7) are correspondingly lost in the relevant TLR
knock-out MutuDC lines (Figure 9C).
In addition, MutuDC lines lacking the Ifnar1 (1IFNR−/−)
were also generated and compared to WT MutuDC lines for
gene expression in response to different combinatorial stimula-
tions by Nanostring technology, as in Figure 7B. Interestingly,
several genes were found to be differentially regulated upon stim-
ulation in 1IFNR−/− versus WT MutuDC lines (Figure A5 in
Appendix), with positive and negative effects of the 1IFNR as
summarized in Figure 7C. In absence of the 1IFNR, the upreg-
ulation of certain genes such Tnfa and Pdl1 was enhanced,
suggesting a negative regulatory effect of the 1IFNR. In con-
trast, other genes showed limited upregulation in 1IFNR−/−
MutuDC lines, suggesting a positive role of the 1IFNR on their
expression. The latter included Ifnb as expected (positive reg-
ulatory effect of 1IFN on 1IFN production), as well as Il10
and Ccr7.
Table 1 shows a list of the MutuDC lines that are currently
available and in the process of being generated (“in progress”),
including lentivirally transduced DC lines, or DC originating from
genetically modified mice.
DISCUSSION
The technical difficulties to obtain substantial numbers of viable
primary DC (Figure 3) are one major argument in favor of the
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FIGURE 9 | Genetically modified MutuDC lines. (A) One representative
example of lentiviral transduction of MutuDC lines is shown, with H-2Kd
over-expression and efficient induction of H-2Kd-restricted antigen
presentation. H-2Kd-positive or control (untransduced) MutuDC lines were
loaded with titrating amounts of the PbCs peptide as indicated and co-cultured
with the relevant cognate T1 TCR-Tg CD8 T cells. (B,C) Representative
genetically modified MutuDC lines are shown, deficient for Tlr3 and Tlr9. WT
(n=3), Tlr3−/− (n=4) or Tlr9−/− (n=3) MutuDC lines were stimulated with
PolyIC or CpG and analyzed after 18 h by FACS for the activation markers
CD40 and CD80. (B) Similarly, the MutuDC lines were stimulated with
different combinations of CpG, PolyIC, IFNγ, and aCD40 and analyzed after
18 h by ELISA on supernatants for IL-12 p40 and p70 secretion (n= 1) (C).
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use of DC lines in screening or preliminary experiments, prior to
confirmation using DC ex vivo or in vivo. However, there is only a
limited number of DC lines and DC culture systems described at
present (van Helden et al., 2008; Inaba et al., 2009).
The MutuDC lines we here describe rely on cellular trans-
formation driven by the SV40 large T oncogene. Strategies for
the derivation of DC lines by oncogene-driven immortaliza-
tion have been previously described, including the use of bone
marrow from SV40-LgT-temperature sensitive-transgenic mice
(SVDC line, derived with GM-CSF, at 33˚C; Ebihara et al., 2004).
The resulting SVDC line represents an enhancement to GM-CSF-
driven BMDC given the relatively larger number of cells available,
but the requirement of culture at 33˚C may represent a techni-
cal limitation. A second cell line, the SRDC line, with a CD8a+
phenotype, results from transformation of splenic DC in vitro
by transfection with a plasmid coding for SV40 LgT (Ruiz et al.,
2005). A third cell line is the DC 2.4 cell line, based on supertrans-
fection with myc and raf in GM-CSF-transduced BM cells (Shen
et al., 1997). In contrast to previous studies, the MutuDC lines we
describe result from transformation of DC in vivo. With expression
of the SV40LgT oncogene under the CD11c promoter, transfor-
mation is not only primarily restricted to DC, but it occurs at the
late stages of DC ontogeny when CD11c is highly expressed and in
particular in the CD8a+ cDC subset (Steiner et al., 2008). Within
the first days of culture, a large majority (ca. 90%) of DC tumor
cells die, suggesting that DC tumor cells are not as yet immortal.
Rather, immortalization is achieved by the spontaneous selection
of the minority of DC tumor cells that stabilize their survival and
growth in culture. Other non-oncogene-driven DC lines previ-
ously reported include the D1 cells, derived from mouse spleen DC
under the strict supplementation of GM-CSF and other fibroblast-
derived growth factors, that require maturation by LPS stimulation
(Winzler et al., 1997; Mortellaro et al., 2009). Importantly, and
also in contrast to previously described DC lines, the derivation
of the MutuDC lines we report does not require any additional
growth factors nor culture conditions (e.g., temperature/CO2),
nor supplementary induction of maturation by LPS.
Given the complexity of the DC system, with phenotypic and
functional heterogeneity amongst DC subsets, the equivalence of
DC lines to a normal DC subset counterpart is crucial. We have
addressed in detail the equivalence of the MutuDC lines by direct
comparison to freshly isolated normal and WT splenic cDC sub-
sets. Altogether, we show that the MutuDC lines have retained
the major characteristics of the splenic CD8α+ cDC subset. These
feature the expression of major surface markers characteristic of
splenic CD8α+ cDC (DEC205, CD24, and Clec9a, while no expres-
sion of CD4 and CD172), as well as upregulation of co-stimulatory
markers in response to TLR-Ls, including a response to PolyIC
(TLR3-L) and not to R-848 (TLR7-L), in agreement with their pro-
file of TLR expression (TLR3+TLR7-). The MutuDC lines showed
comparable or superior secretion of IL-12. It is possible that the
fitness of MutuDC lines in culture, compared to the rapid death of
splenic cDC ex vivo, accounts at least in part with such superior-
ity in MutuDC lines. In addition, MutuDC lines could efficiently
present antigen in the context of both MHC-II and MHC-I,
including direct antigen presentation and the cross-presentation
of cell-associated antigens.
Once established, the MutuDC lines are readily cultured for
months, representing a potent DC research tool, being possible to
readily obtain millions of cells that survive and continue grow-
ing in normal culture conditions. The upregulation of activation
markers and IL-12 p40 secretion remained comparable between
passages 33 and 98, that is, following at least 12 months in cul-
ture (Figures A6A,B in Appendix). In contrast, the capacity to
secrete IL-12 p70 was severely diminished at p98 (Figure A6B in
Appendix). The MutuDC lines are therefore generally not used
after around 50 passages. Nevertheless, the capacity to produce IL-
12p70 could be restored upon adoptive transfer of MutuDC line
cells in vivo (data not shown).
The availability of the MutuDC line cells is in remarkable con-
trast to the scarcity, workload and costs that obtaining one million
CD8α cDC demands, added to the few hours survival of the freshly
isolated cDC in culture. Further to the culture of millions of DC
without a timeframe limitation, perhaps the most outstanding
advantage of the MutuDC line system is the number of mice that
it can replace, potentially being in the order of billions of mice.
Based on the final yield (Figures 3B,C), at least 10 mice were
required to isolate 106 viable CD8α+ cDCs and ca. 2.5 mice to
isolate 106 CD8α− cDCs. This is valuable for the implementation
of the 3R principle in animal experimentation, namely “Reduce,
Refine, and Replace,” particularly relevant in the context of DC
research, given the scarcity of tools for in vitro research and the
difficulties in experimentation in vivo. For instance, in order to
have enough mRNA material for the Nanostring hybridization
that we performed, a total of 18 million cells was required to ana-
lyze the 12 different stimulations in duplicate (Figure 7). At our
estimated 105 CD8α+ cDC obtained per mouse, this requirement
in cell numbers would have been equivalent to the use of at least
180 mice. In addition to the workload and costs of DC isolation,
the DC need to maintain their fitness in culture during the 20 h
stimulation (particularly for mRNA isolation), which is not pos-
sible using freshly isolated cDC. Clearly technically advantageous,
with both excellent yield and viability, the MutuDC lines allow the
performance of large-scale experiments that would otherwise be
extremely difficult if not impossible using freshly isolated DC.
It has also been possible to generate several genetically
modified MutuDC lines, either from breedings, crossing the
CD11c:SV40LgT-TG mice to other genetic backgrounds of inter-
est, or by lentiviral transduction of MutuDC lines (Table 1).
Genetic backgrounds that alter DC ontogeny or homeostasis
may potentially lead to the generation of DC tumors other
than CD8α+ cDC tumors. A strategy to generate splenic CD11b
MutuDC lines is currently underway, which consists in crossing the
CD11c-SV40LgT-TG mice to BATF3-deficient mice, which lack
the CD8α+ DC subset, potentially resulting in the development of
DC tumors of the CD11b subtype.
In point of fact, MutuDC lines share with BM-DC many of their
advantages over primary DC (ex vivo), such as the high num-
bers and the fitness of the cells that can be achieved. However,
MutuDC lines remain more advantageous than BM-DC as they
can be maintained in culture over months as opposed to the few
days period where BM-DC can be used experimentally. Per mouse,
the number of cells obtained is also much superior in MutuDC
lines (expansion for over 50 passages once established) compared
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to the repetitive sacrifice of mice needed for BM-DC cultures (in
the range of 107–108 cells obtained per mouse for the GM-CSF
derivation and 106–107 for the Flt3L derivation).
Both MutuDC lines and BM-DC share concerns on their equiv-
alence to normal DC subsets found in vivo. In contrast to the
relatively heterogeneous DC that are obtained by BM differentia-
tion in BM-DC, the MutuDC lines are homogeneous and resemble
the CD8α+ subset. This is both an advantage and a limitation
depending on the research interest. Noteworthy, the interest in
the CD8α+ cDC subset has been exponentially increasing over
recent years, with the identification of its functional equivalent in
humans (Poulin et al., 2010; Villadangos and Shortman, 2010).
This subset has unique capacities to cross-present cell-associated
antigens and to induce Th1 and CTL responses, and is therefore of
central interest in vaccine science and immunotherapy, including
strategies to target antigens to the CD8α+ subset (Hildner et al.,
2008; Shortman and Heath, 2010). At present, the majority of DC
culture systems, including DC lines and BM-DC, rely on growth
factors such as GM-CSF, which preferentially expand the CD11b+
CD24− (CD8α−) subset of DC (Shen et al., 1997; Winzler et al.,
1997; Ebihara et al., 2004; Naik et al., 2005; Mortellaro et al., 2009).
In order to obtain DC cultures of the CD8α+ subset, DC are gen-
erally derived from BM using Flt3L rather than GM-CSF (Naik
et al., 2005). Only one DC line with a CD8α+ phenotype has been
previously reported, the SRDC line (without further follow-up
studies; Ruiz et al., 2005).
The MutuDC lines we here report are therefore uniquely inter-
esting as we validate that they have retained the major char-
acteristics of the CD8aα+ cDC subset by direct comparison to
their normal counterpart, they are readily manipulated and show
excellent viability in culture. Overall, the MutuDC lines have the
potential to serve as a powerful tool for screening and prelim-
inary experimentation, in particular when the cross-presenting
CD8α+ cDC subset is investigated. Artifacts arising due to the
SV40LgT-driven tumorigenesis and immortalization of MutuDC
lines cannot be excluded, and findings made in MutuDC lines need
careful confirmation in normal DC and in vivo.
For instance, we have recently shown that Type I Interferon
induces apoptosis preferentially in the splenic CD8α+ subset fol-
lowing PolyIC stimulation and could show the role of BH3-only
proteins in this process in vivo (Fuertes Marraco et al., 2011).
Notably, the MutuDC lines strongly assisted our studies: screening
of TLR-Ls and kinetic studies in MutuDC lines preceded targeted
experimentation in vivo. This was critical to choose parameters
as simple as the range of time-points to be analyzed, but also to
choose the genetic deficiencies that could confirm the proteins
involved in the process by first screening for apoptotic proteins
with western blot analyses in MutuDC lines. Conversely, following
the observation that the 1IFNR was involved in splenic cDC deple-
tion, the induction and role of IFNβ in DC apoptosis was more
thoroughly investigated in vitro using the MutuDC lines. Notably,
it was determined that TLR3 is necessary for induction of IFNβ in
CD8α+ DC (in isolation, in vitro), and that exogenous IFNβ alone
could induce apoptosis. The latter experiments were performed
first using MutuDC lines, prior to the experiments on IFNβ pro-
duction and induction of apoptosis using WT and PRR knock-out
mice. Furthermore, the availability of 1IFNR−/− MutuDC lines
has also been of benefit for the in-house production of IFNβ
and was used to prove that IFNβ alone was sufficient to induce
MutuDC line apoptosis and splenic DC depletion.
Altogether, the effective strategy for DC research using MutuDC
lines is a compromise between firstly, screening and performing
as many experiments as needed in the MutuDC lines to acquire
preliminary evidence on a given aspect of DC biology, and sec-
ondly, ultimate confirmation in vivo. The use of MutuDC lines
has the potential to enormously expand the range of experi-
mental parameters, conditions and biological candidates to be
considered by allowing extensive preliminary experimentation,
and subsequently greatly reduce the number of experiments,
time, materials, and finally, mice that are needed for in vivo
experimentation.
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APPENDIX
PROTEOMICS
Sample preparation
The MutuDC1940 was subjected to SILAC labeling, by culture
in complete medium with natural arginine and lysine replaced
by heavy isotope-labeled l-arginine-U-13C6-15N4 and l-lysine-
U-13C6-15N2 (Cambridge Isotope Laboratories, Andover, MA,
USA) as described previously (Ong et al., 2002; MCP 2002, 376-
86). SILAC-labeled MutuDC1940 and ex vivo-purified CD8a+
DCs were washed in PBS and immediately frozen on dry ice.
Cells were lysed in 2x LDS sample buffer (NuPAGE, Invitro-
gen), mixed 1:1 based on cell numbers, and separated by 1D-SDS
PAGE (4–12% Bis-Tris Mini-Gel, Invitrogen). After Colloidal Blue
Staining (Invitrogen), gel pieces were excised from the gel and sub-
jected to reduction, alkylation, and in-gel digestion with sequence
grade modified trypsin (Promega) as described (Shevchenko et al.,
1996). After digestion, peptides were extracted by 30% acetonitrile
in 3% TFA in water, reduced in a speedvac, and desalted using
StageTips before analysis by MS (Rappsilber et al., 2003).
MS ANALYSIS
A Proxeon easy-nLCII (Thermo Fisher Scientific) was directly
connected to a LTQ-Orbitrap VELOS mass spectrometer
(Thermo Fisher Scientific) via a nanoelectrospray ion source
(Thermo Fisher Scientific). Peptides were separated by reverse
phase chromatography using in-house-made C18 microcolumns
(75µm ID packed with ReproSil-Pur C18-AQ 3µm resin, Dr.
Maisch, GmbH) with a 120 min gradient from 5 to 60% acetoni-
trile in 0.5% acetic acid at a flow rate of 200 nL/min. Background
ions were reduced using an ABIRD device (ESI Source Solutions).
The LTQ-Orbitrap VELOS was operated in the data-dependent
mode dynamically choosing the 10 most intense ions from the
survey scan (300–1850 Th) for fragmentation using HCD. Pre-
cursor ion charge state screening was enabled and all unassigned
charge states as well as singly charged species were rejected. Data
were acquired using Xcalibur software.
DATA ANALYSIS
Raw data files were analyzed using MaxQuant software (ver-
sion 1.1.1.27) as described (Cox and Mann, 2008). Andromeda,
a probabilistic search engine incorporated into the MaxQuant
framework (Cox et al., 2010), was used to search the peak lists
against the mouse IPI database version 3.68. Enzyme specificity
was set to trypsin and a maximum of three missed cleavages were
allowed. Carbamidomethyl cysteine was set as a fixed modifica-
tion, N-terminal acetylation and methionine oxidation as variable
modifications. The false positive rate was set to 1% at the pep-
tide and 1% at the protein level with a minimum required peptide
length of 6 amino acids. Proteins quantified by less than two ratio
counts and frequently observed contaminants were removed.
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FIGURE A1 | MutuDC lines show a mRNA profile of DC markers
similar to splenic CD8α+ cDC. In complement to the analysis in
Figure 4, levels of mRNA for the indicated genes were quantified by
Nanostring technology in 13 different MutuDC lines and compared to
freshly sorted splenic cDC subsets (n=3 per subset). Error bars
indicate SD.
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FIGURE A2 | Most MutuDC lines restore CD8α expression and
downregulate CD11b upon adoptive transfer in vivo. (A) Experimental
outline: MutuDC lines (n=4) were analyzed directly from culture or following
intra-veinous adoptive transfer of 3×106 cells per MutuDC line into
immunodeficient rag2−/−γc−/− hosts. Spleens containing MutuDC line cells
(tumors) were analyzed 16 days after injection. (B) Gating strategy for the flow
cytometry analysis of MutuDC lines in culture versus tumors in MutuDC
line-injected mice. MutuDC lines and normal WT splenic cDC subsets (used
as controls) were gated as indicated (and as previously described in
Figure 4A). MutuDC line cells in tumoral splenocytes from MutuDC
line-injected mice were gated based on eGFP expression as indicated. (C) The
expression of surface markers CD8α and CD11b was analyzed in MutuDC
lines before injection versus following adoptive transfer in vivo and
standardized relative to the levels found in normal WT splenic cDC subsets
(controls). For CD8α expression, the CD8α+ (CD11b−) cDC subset represents
100% and the CD8α− (CD11b+) cDC subset represents 0%, and vice versa for
CD11b expression. Arrows indicate the change in surface marker expression
for each particular MutuDC line.
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FIGURE A3 | Proteome analysis of DC line MutuDC1940 versus splenic
CD8α+ cDC. Lysates of the DC line MutuDC1940 and freshly isolated
splenic CD8α+ cDC were analyzed as detailed in Appendix and previously
described (Luber et al., 2010). The MutuDC1940 was SILAC-labeled and
mixed 1:1 with primary CD8α+ cDCs. (A) Histogram of the frequency
distribution of ratios from MutuDC1940 (H) versus ex vivo CD8α+ cDCs (L).
Center of the bins are indicated. (B) Ratios of all quantified protein as
boxplot with median and whiskers from 5 to 95 percentile.
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FIGURE A4 |Transfection and electroporation of MutuDC lines.
MutuDC line transfectability was tested using classical approaches such
as calcium phosphate (CaPi) (A,B), JetPEI (C) or electroporation (D). The
DsRedExpress (A–C) or pmaxGFP vectors (D) were used as test
examples. CaPi transfection efficiency (A) and consequent upregulation
of activation markers (B) 24 h post-transfection measured by flow
cytometry (filled gray: negative control, open gray: mock transfection,
open black: DsRedExpress transfected cells). (C) Transfection using
JetPEI, with much weaker reporter gene expression as compared to
CaPi in (A). Electroporation efficiency and cell survival (D) at 24 h using
several Amaxa electroporation programs with endotoxin free plasmid or
electroporation solutions alone (Solution L and Solution V). In both
electroporation and transfection (whether CaPi or JetPEI), all positive
cells died within 72 h (data not shown).
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FIGURE A5 | Lack of the 1IFNR in MutuDC lines has a positive or negative
impact on mRNA expression of several genes upon stimulation. WT
(n=2) or 1IFNR (n=2) MutuDC lines were stimulated for 20 h with different
combinations of CpG, PolyIC, IFNγ, and aCD40 as indicated and described in
Figure 7B, and analyzed by Nanostring technology. Figure 7C provides a
summary table for the positive or negative effects of the 1IFNR on mRNA
expression of several genes upon stimulation. Here, representative examples
of positive (A) or negative (B) effects (four per group) are shown. Upon
stimulation, the decrease in mRNA expression due to lack of 1IFNR
(“positive” effect of 1IFNR) was 2- to 13-fold for il10, 3- to 17-fold for Ifnβ, 5-
to 20-fold for Gmcsf and 5- to 36-fold for Serpinb1a. On the other hand the
lack of 1IFNR resulted in an increase in mRNA expression (“negative” effect
of 1IFNR) that was 4- to 10-fold for Cxcl9, 3- to 7-fold increase for Ccl3, 3 to
18-fold for B7dc and 2- to 13-fold for Tnfa.
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FIGURE A6 | MutuDC lines keep their ability to upregulate activation
markers upon stimulation even at high passage numbers. (A) Cells with
low (33, open bars) or high (98, black bars) passage number were stimulated
for 20 h with different combinations of CpG, PolyIC, IFN-g, and aCD40 as
indicated. Analysis of CD40 expression by flow cytometry is shown (similar
results were obtained for CD80, CD86, and MHC-II, data not shown). (B)
MutuDC lines at p33 or p98 were stimulated as indicated [similar to (A)] and
were analyzed for IL-12 p40 and p70 secretion in the cell culture supernatants.
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